Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Rosie Hawkins wanted to give son Jonathan, six, and daughter Freya, one, letters to remember her by right into old age ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Investor's Business Daily on MSN4d
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...
A MUM-of-two diagnosed with terminal breast cancer after her second round of IVF has written cards for both of her children ...
In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback